DZ Bank Reaffirms Sell Rating for Rhoen Klinikum (RHK)

Rhoen Klinikum (ETR:RHK)‘s stock had its “sell” rating reiterated by investment analysts at DZ Bank in a research note issued on Wednesday, December 13th.

RHK has been the topic of a number of other reports. Baader Bank set a €24.00 ($28.57) price objective on Rhoen Klinikum and gave the company a “neutral” rating in a report on Friday, November 10th. Warburg Research set a €26.30 ($31.31) price objective on Rhoen Klinikum and gave the company a “neutral” rating in a report on Monday, November 13th. Independent Research set a €32.00 ($38.10) price objective on Rhoen Klinikum and gave the company a “neutral” rating in a report on Monday, November 13th. Deutsche Bank set a €22.00 ($26.19) target price on Rhoen Klinikum and gave the stock a “neutral” rating in a report on Friday, December 1st. Finally, Commerzbank set a €25.00 ($29.76) target price on Rhoen Klinikum and gave the stock a “neutral” rating in a report on Friday, November 10th. Four analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. Rhoen Klinikum currently has an average rating of “Hold” and an average price target of €25.05 ($29.82).

Rhoen Klinikum (ETR:RHK) traded down €0.07 ($0.08) during mid-day trading on Wednesday, hitting €29.88 ($35.57). The company had a trading volume of 17,087 shares, compared to its average volume of 42,547. The firm has a market cap of $2,010.00 and a price-to-earnings ratio of 1,494.00. Rhoen Klinikum has a 1-year low of €22.66 ($26.98) and a 1-year high of €30.65 ($36.49).

TRADEMARK VIOLATION WARNING: “DZ Bank Reaffirms Sell Rating for Rhoen Klinikum (RHK)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/30/rhon-klinikum-aktiengesellschaft-rhk-rating-reiterated-by-dz-bank.html.

Rhoen Klinikum Company Profile

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services in the areas of cardiological and coronary diseases, neurological disorders, oncology, lung diseases, and orthopedic and accident surgeries; rehabilitation services; and thoracic, pulmonary and vascular diseases, tumors, heart conditions, and nervous and skeletal system diseases.

Analyst Recommendations for Rhoen Klinikum (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply